The FDA accepts diaMentis Technology to Diagnose Mental Health Issues

Quebec-based medical technology developer diaMentis announced on December 17, 2020, that its mental health diagnostic technology has been accepted in the U.S. Food and Drug Administration (FDA) Breakthrough Devices Program.

Once approved, diaMentis technology could provide primary care physicians and psychiatrists with an objective method for diagnostic decision-making, especially for patients suffering from bipolar disorder or schizophrenia.

There are currently no tools available to assist with mental health diagnoses anywhere in the world. This FDA Breakthrough Devices Program acceptation is an important recognition because, at the moment, diagnoses in this field are based solely on observation of clinical signs and symptoms and can take, in some cases, up to 5 or 7 years to be confirmed.

BCF is proud to have contributed to the intellectual property strategy of diaMentis with a team composed of Tuba Yamaç, Benjamin Koopferstock in collaboration with Louis Carbonneau of Tangible IP.

To read the full press release, click here